Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1No longer available 1

Sponsor Class

NIH 3INDUSTRY 3OTHER 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Lymphoid 13Sarcoma 6Other solid neoplasm 5Thoracic 4Genitourinary 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Prostatic Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Mesothelioma, Malignant 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × tazemetostat × Genitourinary × Clear all
NCT07407283 2026-04-21

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT04179864 2026-03-10

CELLO-1

Ipsen

Phase 1/2 Terminated
102 enrolled 39 charts
Genitourinary

Prostatic Neoplasms

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Ipsen

No longer available
GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡